Abstract Number: 0741 • ACR Convergence 2023
Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors
Background/Purpose: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are oral hypoglycemic agents for Type II diabetes mellitus (T2D) now prescribed for renal and cardiovascular indications. Patients…Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…Abstract Number: 1014 • ACR Convergence 2023
Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities
Background/Purpose: Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer therapies. However, ICIs may be associated with significant immune-related adverse events (irAEs), including rheumatic irAEs.…Abstract Number: 1529 • ACR Convergence 2023
Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients
Background/Purpose: Mycophenolate mofetil (MMF) is a first-line immunosuppressant treatment for systemic sclerosis (SSc), particularly for patients with interstitial lung disease (ILD) and diffuse skin involvement.…Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium
Validation of Serious Adverse Event Reporting in a Multicenter Registry
Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…Abstract Number: 0291 • ACR Convergence 2022
Tofacitinib Leads to Significant Weight Gain – A Real Life Experience of 429 Patients
Background/Purpose: Tofacitinib(Tofa) an oral Janus kinase inhibitor(JAK) has shown good promise in the management of rheumatoid arthritis and psoriatic arthritis. While being increasingly used in…Abstract Number: 1131 • ACR Convergence 2022
Integrating Genome and Transcriptome-Wide Associations with Real-World Data to Assess Risk for Leukopenia in Patients Taking Azathioprine
Background/Purpose: Azathioprine is used to treat several autoimmune conditions, but its use is limited by side effects. Leukopenia, a severe, potentially life-threatening side effect is…Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…Abstract Number: 1133 • ACR Convergence 2022
Ancestry, ACKR1, and Leucopenia in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem condition that occurs more frequently in certain racial groups, particularly in populations of African ancestry. Low white…Abstract Number: 0436 • ACR Convergence 2022
Clinical Characteristics and Outcome of ANCA-Associated Vasculitides Induced by Anti-Thyroid Drugs: A Multicenter Retrospective Cohort Study
Background/Purpose: ANCA-associated vasculitides (AAV) induced by anti-thyroid drugs (ATD) is a well-known entity. However, characteristics, requirement for immunosuppressive agents and the risk of relapse remain…Abstract Number: 1134 • ACR Convergence 2022
Genome-wide Association Study Identifies Novel Loci for Leukopenia Among TPMT and NUDT15 Normal Metabolizers Taking Azathioprine
Background/Purpose: Azathioprine is a thiopurine drug used for the treatment of several inflammatory and autoimmune conditions. However, its use is limited due to side effects,…Abstract Number: 0461 • ACR Convergence 2022
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
Background/Purpose: Hemoglobin A1c (HbA1c) is used clinically to estimate patients' average blood glucose over the preceding few months and is affected by glycemic as well…Abstract Number: 1283 • ACR Convergence 2022
Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy
Background/Purpose: Some of the most commonly reported side effects of statins (widely used lipid lowering agents) are muscle injury (incidence ranging from 0.1-20% based on…Abstract Number: 0653 • ACR Convergence 2022
JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro
Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »
